# To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients

> **NCT02723591** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 599 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** Tacrolimus immediate release

## Key facts

- **NCT ID:** NCT02723591
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-09
- **Primary completion:** 2019-06-14
- **Final completion:** 2019-06-14
- **Target enrollment:** 599 (ACTUAL)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02723591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02723591, "To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02723591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*